Boehringer Ingelheim, Sanofi to Produce Biopharmaceuticals

Jan 19, 2015

Boehringer Ingelheim and Sanofi announced a strategic alliance to extend Sanofi’s manufacturing capacity network for therapeutic monoclonal antibodies, according to a press release. Boehringer Ingelheim’s cell culture operations will provide contract manufacturing capacities to support the production of Sanofi’s biologics pipeline.

Under the terms of the agreement Sanofi will have access to Boehringer Ingelheim’s capabilities to transfer and manufacture therapeutic monoclonal antibodies for global market supply. Initial product transfers will begin in early 2015 per the press release.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments